Survodutide

Reconstitution

This compound ships pre-mixed as a ready-to-use liquid — do not add bacteriostatic water. The units below assume the vial already holds 5 mg/mL.

Dose to syringe units

On a standard 100-unit (1 mL) insulin syringe, at the concentration above:

Amounts listed in the Dosify Me data: 300–4800 mcg. Frequency: weekly. Timing: same day each week, any time.

All vial sizes reconstitute to 5mg/mL (50mcg/unit) so the syringe reads the same regardless of size.

Reading units for Survodutide

• Syringe units measure volume, not the amount of Survodutide: on a U-100 insulin syringe 100 units is 1 mL.
• Survodutide ships ready to use, so no water is added. The strength on the label is 5 mg/mL, so one syringe unit holds 0.05 mg.

Check one row of the table above: 300 mcg is 0.3 mg; 0.3 mg ÷ 5 mg/mL = 0.06 mL; 0.06 mL × 100 = 6 units.

What it does

• A GLP-1/glucagon dual receptor agonist, in the same class as mazdutide, developed for obesity and liver disease (MASH).
• The GLP-1 side acts on appetite-regulating brain regions to reduce how much food the brain wants to take in, while also slowing gastric emptying to extend fullness after meals.
• The glucagon side acts mainly on the liver, increasing energy expenditure and helping mobilize and burn stored fat — this dual action is what drives its added benefit for liver fat (MASH) on top of weight loss.
• Late-stage clinical trials show significant weight loss and improvements in liver fat.
• Not yet independently FDA-approved — still in clinical development as of this writing.

Why it is listed under Weight Loss & Metabolic

• Weight Loss & Metabolic: Dual agonist showing significant weight loss in late-stage trials.

What users report

Anecdotal and early-research reports, kept apart from the evidence above. Not clinically established.

• Trial participants and users report strong appetite suppression and the same quieting of 'food noise' as other GLP-1-class drugs.
• Reduced liver fat is reported in trial data and is the main reason it is being developed for fatty liver disease; not yet an approved use.
• Some report higher energy expenditure — feeling warm, sweating more — attributed to the glucagon-receptor activity.
• As with the GLP-1 class, reduced alcohol interest is sometimes reported and unverified.

Side effects

• Nausea, vomiting, diarrhea, constipation — usually mild and transient.
• Modest resting heart rate increase.
• Still in Phase 3; real-world data limited.

Medication caution

Survodutide calculator

Different vial or dose? Open the Survodutide reconstitution calculator, pre-filled with these numbers.

Frequently asked

How many units is 300 mcg of Survodutide?

At 5 mg/mL (the concentration every vial size mixes to), 300 mcg of Survodutide is 6.0 units on a 100-unit insulin syringe (0.060 mL).

How many units is 600 mcg of Survodutide?

At 5 mg/mL (the concentration every vial size mixes to), 600 mcg of Survodutide is 12.0 units on a 100-unit insulin syringe (0.120 mL).

How many units is 1.2 mg of Survodutide?

At 5 mg/mL (the concentration every vial size mixes to), 1.2 mg of Survodutide is 24.0 units on a 100-unit insulin syringe (0.240 mL).

How much bacteriostatic water do I add to a 10 mg vial of Survodutide?

2.00 mL, which gives 5 mg/mL. This compound ships pre-mixed, so no water is added.

How often is Survodutide taken?

Weekly. Same day each week, any time Typical cycle: Often run continuously; tapering is done under guidance.

Sources

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (PubMed)
• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (NEJM)
• Survodutide (glucagon/GLP-1 dual agonist): Phase III weight-loss results (Boehringer Ingelheim)

Related pages and guides

• Survodutide calculator
• How many units is 250 mcg?
• U-100 vs U-50 insulin syringe for peptides
• How to track peptide doses
• All peptide guides